Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C2656
http://purl.obolibrary.org/obo/NCIT_C2656
|
|---|---|
| Preferred Name | Halofuginone Hydrobromide |
| Definitions |
The hydrobromide salt of halofuginone, a semisynthetic quinazolinone alkaloid anticoccidial derived from the plant Dichroa febrifuga, with antifibrotic and potential antineoplastic activities. Halofuginone specifically inhibits collagen type I gene expression and matrix metalloproteinase 2 (MMP-2) gene expression, which may result in the suppression of angiogenesis, tumor stromal cell development, and tumor cell growth. These effects appear to be due to halofuginone-mediated inhibition of the collagen type I and MMP-2 promoters. Collagen type I and MMP-2 play important roles in fibro-proliferative diseases.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | The hydrobromide salt of halofuginone, a semisynthetic quinazolinone alkaloid anticoccidial derived from the plant Dichroa febrifuga, with antifibrotic and potential antineoplastic activities. Halofuginone specifically inhibits collagen type I gene expression and matrix metalloproteinase 2 (MMP-2) gene expression, which may result in the suppression of angiogenesis, tumor stromal cell development, and tumor cell growth. These effects appear to be due to halofuginone-mediated inhibition of the collagen type I and MMP-2 promoters. Collagen type I and MMP-2 play important roles in fibro-proliferative diseases. |
|---|---|
| prefLabel | Halofuginone Hydrobromide
|
| label | Halofuginone Hydrobromide
|
| PDQ_Closed_Trial_Search_ID | 38485
|
| code | C2656
|
| Has_Target | |
| prefixIRI | NCIT:C2656
|
| in_subset |
See more
See less
|
| Display_Name | Halofuginone Hydrobromide
|
| Preferred_Name | Halofuginone Hydrobromide
|
| FDA_UNII_Code | PTC2969MV1
|
| Contributing_Source |
CTRP
FDA
|
| Chemical_Formula | C16H17BrClN3O3.BrH
|
| Maps_To | Halofuginone Hydrobromide
|
| CAS_Registry |
17395-31-2
64924-67-0
|
| NSC Number | 713205
|
| NCI_Drug_Dictionary_ID | 38485
|
| Legacy Concept Name | Halofuginone_Hydrobromide
|
| Has_Free_Acid_Or_Base_Form | |
| type | |
| ALT_DEFINITION | A substance that is being studied for its ability to slow the growth of connective tissue and to prevent the growth of new blood vessels that tumors need to grow. It is a type of quinazolinone alkaloid and a type of antiangiogenesis agent.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 38485
|
| Accepted_Therapeutic_Use_For | Scleroderma and Antiprotozoal; Coccidiosis (Vet).
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C0521922
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |